ArticleChemistry & biodiversity2026
In Vitro Antimicrobial Activity and In Vivo Intestinal Barrier Regulation by Commiphora leptophloeos Bark Extract in 5-Fluorouracil-Induced Mucositis.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
This study evaluated the phytochemical composition, antimicrobial activity, and in vivo protective effects of the hydroethanolic extract from Commiphora leptophloeos stem bark (HECL) against 5-fluorouracil (5-FU)-induced intestinal mucositis. Despite the extensive traditional use of C. leptophloeos in gastrointestinal disorders, its stem bark extract has not yet been chemically characterized nor systematically investigated in experimental models of chemotherapy-induced intestinal injury. Phytochemical analysis by mass spectrometry identified 21 metabolites, mainly procyanidins and flavonoids. Antimicrobial screening against 90 bacterial strains showed selective inhibition of Gram-positive bacteria at 40-80 µg/mL. In vivo, mucositis was induced in female Swiss mice with 5-FU (450 mg/kg, i.p.). Treatment with HECL (10 mg/kg) significantly preserved villus and crypt architecture (p < 0.05) and reduced IL-6 levels (p < 0.05). HECL also increased MUC-2 expression (p < 0.05), while maintaining intestinal barrier integrity, as indicated by occludin immunostaining. Additionally, the extract modulated oxidative stress (malondialdehyde) and acetylcholinesterase activity. Overall, HECL demonstrated bioactive potential with broad-spectrum antimicrobial activity and protective effects against chemotherapy-induced intestinal injury, supporting its role as a therapeutic adjuvant in intestinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.